Regenerex Pharma terminates CFO Kenneth Perry for cause; appoints Don E. Ray as interim CFO

REGENEREX PHARMA, INC.

Kenneth Perry placed on administrative suspension with pay on March 31, 2026.
Board determined Perry's conduct constituted material breach and 'Cause' under employment agreement; termination effective May 2, 2026.
Don E. Ray appointed Interim CFO effective April 1, 2026 for an initial 90-day term.
CEO Greg Pilant recused himself from deliberations; independent board made decision.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Don E. Ray

Interim Chief Financial Officer

RGPX · REGENEREX PHARMA, INC.

Effective: 2026-04-01
Filed: May 6, 2026, 7:59 PM ET

In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.

Departed (interim)

Kenneth Perry

Chief Financial Officer

RGPX · REGENEREX PHARMA, INC.

Effective: 2026-05-02
Successor: Don E. Ray
Filed: May 6, 2026, 7:59 PM ET

Following the Committee’s review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry’s employment for Cause, with notice of such termination delivered on May 2, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Don E. Ray was appointed as Interim Chief Financial Officer at REGENEREX PHARMA, INC..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

In connection with the foregoing, on April 1, 2026, the Board appointed Don E. Ray to serve as Interim Chief Financial Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth Perry was terminated as Chief Financial Officer at REGENEREX PHARMA, INC..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

Following the Committee’s review and recommendation, the Independent Board of Directors approved the termination of Mr. Perry’s employment for Cause, with notice of such termination delivered on May 2, 2026.

View on SEC.gov

REGENEREX PHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001472375-26-000133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.